B
Barbara Sleight
Researcher at Pfizer
Publications - 23
Citations - 1499
Barbara Sleight is an academic researcher from Pfizer. The author has contributed to research in topics: Inotuzumab ozogamicin & Population. The author has an hindex of 8, co-authored 20 publications receiving 1053 citations.
Papers
More filters
Journal ArticleDOI
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Hagop M. Kantarjian,Daniel J. DeAngelo,Matthias Stelljes,Giovanni Martinelli,Michaela Liedtke,Wendy Stock,Nicola Gökbuget,Susan O'Brien,Kongming Wang,Tao Wang,M. Luisa Paccagnella,Barbara Sleight,Erik Vandendries,Anjali S. Advani +13 more
TL;DR: The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotzumabozogamic in group had results below the threshold for minimal residual disease.
Journal ArticleDOI
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
Hagop M. Kantarjian,Daniel J. DeAngelo,Matthias Stelljes,Michaela Liedtke,Wendy Stock,Nicola Gökbuget,Susan O'Brien,Elias Jabbour,Tao Wang,Jane Liang White,Barbara Sleight,Erik Vandendries,Anjali S. Advani +12 more
TL;DR: The final INO‐VATE results are reported and additional analyses of patient characteristics associated with improved outcomes are reported, indicating improved outcomes with InO versus standard‐of‐care chemotherapy.
Journal ArticleDOI
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Hagop M. Kantarjian,Daniel J. DeAngelo,Anjali S. Advani,Matthias Stelljes,Partow Kebriaei,Ryan D. Cassaday,Akil Merchant,Naohito Fujishima,Toshiki Uchida,Maria Calbacho,Anna A Ejduk,Susan O'Brien,Elias Jabbour,Hui Zhang,Barbara Sleight,Erik Vandendries,David I. Marks +16 more
TL;DR: The frequency of sinusoidal obstruction syndrome-comprising events occurring during treatment (or follow-up without HSCT) and after treatment and subsequent haemopoietic stem-cell transplantation (HSCT) was higher in the inotuzumab ozogamicin group than in the standard care group, and treatment-emergent hepatotoxicities were more frequent.
Journal ArticleDOI
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)
Erica Brivio,Franco Locatelli,Marta Lopez-Yurda,Andrea Malone,Cristina Díaz-de-Heredia,Bella Bielorai,Claudia Rossig,Vincent H.J. van der Velden,Anneke C.J. Ammerlaan,Adriana Thano,Inge M. van der Sluis,Monique L. den Boer,Ying Chen,Barbara Sleight,Benoit Brethon,Karsten Nysom,Lucie Sramkova,Ingrid Øra,Luciana Vinti,Christiane Chen-Santel,Christian M. Zwaan +20 more
TL;DR: InO was well tolerated, demonstrating anti-leukemic activity in heavily pre-treated children with CD22-positive R/R ALL, and was established as 1.8 mg/m2/course, as in adults.
Journal ArticleDOI
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
Elias Jabbour,Daniel J. DeAngelo,Matthias Stelljes,Wendy Stock,Michaela Liedtke,Nicola Gökbuget,Susan O'Brien,Tao Wang,M. Luisa Paccagnella,Barbara Sleight,Erik Vandendries,Anjali S. Advani,Hagop M. Kantarjian +12 more
TL;DR: A subset analysis compared the efficacy and safety of InO in younger and older patients.